Exclusive: CRISPR delivery startup Spotlight Therapeutics shuts downnews2025-02-19T09:07:05+00:00February 19th, 2025|Endpoints News|
In turnaround, Solid Bio reports promising initial data for Duchenne gene therapynews2025-02-18T16:45:39+00:00February 18th, 2025|Endpoints News|
Arcus touts early kidney cancer data as Gilead declines optionnews2025-02-18T16:34:12+00:00February 18th, 2025|Endpoints News|
Algo’s topical pain treatment fails Phase 2 study with overperforming placebonews2025-02-18T12:40:24+00:00February 18th, 2025|Endpoints News|
#ASCOGU: Lilly’s early bladder cancer data hint at safety edge over J&J’s Balversanews2025-02-15T00:00:06+00:00February 15th, 2025|Endpoints News|
#ASCOGU: Corbus shares dip on mixed Phase 1 solid tumor data for Nectin-4 ADCnews2025-02-14T16:09:11+00:00February 14th, 2025|Endpoints News|
BioNTech vets raise about $90M in Series A for bispecific immunology researchnews2025-02-14T15:49:41+00:00February 14th, 2025|Endpoints News|
Bristol Myers’ Opdualag stumbles in late-stage resected melanoma trialnews2025-02-14T11:53:12+00:00February 14th, 2025|Endpoints News|
Labs fear future funding cuts with Trump administration actions in limbonews2025-02-13T20:57:49+00:00February 13th, 2025|Endpoints News|
Agios’ Pyrukynd succeeds in key trial of rare red blood cell disorder in kidsnews2025-02-13T16:09:32+00:00February 13th, 2025|Endpoints News|
